Clinical trials: Recurrent Head and Neck Carcinoma
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
This is a global, multi-center, Phase 3 study that is randomized 1:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs.
- Conditions
- Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
- Trial name
- VERSATILE-003 (NCT06790966)
- Testing
- Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
- Where
- 28 sites in United States
- Volunteers
- 12 people
- Sponsor
- PDS Biotechnology Corp.
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different…
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06678724
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Cancer
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248560
- Testing
- docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Head and Neck Cancer
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
This study has been designed to evaluate the safety and efficacy of giving seven injections of PepCan or placebo over approximately a 24-month period in subjects with head and neck cancers who achieved remission.
- Trial name
- NCT03821272
- Testing
- PepCan
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Arkansas
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
This phase II trial is studying how well giving carboplatin, paclitaxel, cetuximab, and erlotinib hydrochloride together works in treating patients with metastatic or recurrent squamous cell head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01316757
- Testing
- cetuximab, paclitaxel, carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Fox Chase Cancer Center
Head and Neck Squamous Cell Carcinoma
Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC
Clinical Phase: phase II single arm study Primary Objectives: Response rate Number of Subjects: 27 patients Study Population: recurrent or metastatic head and neck squamous cell carcinoma Investigational Product(s), Dose, and…
- Trial name
- NCT03450967
- Testing
- Durvalumab Plus Tremelimumab
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Samsung Medical Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
Randomized phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic or recurrent head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00033618
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Neoplasms
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this trial is to estimate progression free survival in patients with recurrent or metastatic head and neck cancer that have not received chemotherapy in this setting.
- Trial name
- NCT01057589
- Testing
- Pemetrexed, Cetuximab, Cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Esophagus Cancer
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if Afatinib plus Palbociclib works in previously treated recurrent or metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT06753747
- Testing
- Palbociclib, Afatinib(30mg), Afatinib(40mg)
- Where
- China
- Volunteers
- 45 people
- Sponsor
- West China Hospital
Bladder Cancer, Breast Cancer
Docetaxel in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American…
- Conditions
- Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00003565
- Testing
- docetaxel
- Where
- 74 sites in United States, Canada and 1 more
- Volunteers
- 109 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasm Metastasis
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
- Trial name
- NCT02313012
- Testing
- CC-90003
- Where
- 5 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- Celgene
Nasopharyngeal Carcinoma
Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this study is to determine the maximal tolerated dose (MTD) of re-irradiation using carbon ion radiotherapy (CIRT) in the treatment of locally recurrent nasopharyngeal cancer (NPC) and to evaluate the efficacy of…
- Trial name
- NCT02569788
- Testing
- Carbon ion radiotherapy (CIRT)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Head and Neck Cancer
Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer
This multicenter, open-label, uncontrolled phase II trial evaluates safety and efficacy of post-operative chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck.
- Trial name
- ACCRA-HN (NCT00791141)
- Testing
- Cetuximab
- Where
- 10 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Head and Neck Cancer
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00045669
- Testing
- imatinib mesylate
- Where
- 15 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- University Health Network, Toronto
Head and Neck Cancer, Lung Cancer
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from the side effects of chemotherapy.
- Conditions
- Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00003569
- Testing
- cisplatin, dimesna, paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Head and Neck Carcinoma, Locally Advanced Head and Neck Carcinoma
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
This phase I trial studies the side effects of interstitial photodynamic therapy (I-PDT) in treating patients with head and neck cancer that has spread to other parts of the body or that has come back.
- Trial name
- NCT03727061
- Testing
- Nivolumab, Porfimer Sodium, Interstitial Illumination Photodynamic Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Squamous Cell Carcinoma HNSCC
Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
To evaluate the safety and tolerability of re-irradiation combined with chidamide in patients with recurrent head and neck squamous cell carcinoma after radiotherapy.
- Trial name
- NCT07545967
- Testing
- Chidamide, radiotherapy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.